From The Australian:
... analysts from Cantor Fitzgerald believed Mesoblast had sufficient data to allay the FDA’s concerns.“MESO has potency assays and experience from clinical trials to correlate this potency to measurable clinical outcomes,” the analysts said in a note to investors.“We think MESO will be able to address the concerns that were raised in the briefing materials. The topics of discussion were already anticipated by the company, and MESO has been preparing for the AdCom (advisory committee).”
Add to My Watchlist
What is My Watchlist?
